Abacavir Sulfate

30/08/2021

252

63. Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1999; 43:1708-15. http://www.ncbi.nlm.nih.gov/pubmed/10390227?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=89348&blobtype=pdf

103. Epzicom (abacavir sulfate and lamivudine) tablets risk evaluation and mitigation strategy (REMS). From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM144243.pdf

104. Trizivir (abacavir sulfate, lamivudine, and zidovudine) tablets risk evaluation and mitigation strategy (REMS). From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM144268.pdf

61. Miller V, Ait-Khaled M, Stone C et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS. 2000; 14:163-71. http://www.ncbi.nlm.nih.gov/pubmed/10708287?dopt=AbstractPlus

62. McDowell JA, Chittick GE, Ravitch JR et al. Pharmacokinetics of [¹⁴C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother. 1999; 43:2855-61. http://www.ncbi.nlm.nih.gov/pubmed/10582871?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=89576&blobtype=pdf

105. Ziagen (abacavir sulfate) tablets and oral solution risk evaluation and mitigation strategy (REMS). From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM089831.pdf

106. Food and Drug Administration. Early communication about an ongoing safety review of Ziagen (abacavir) and Videx (didanosine). 2008 July 24. From FDA website. Accessed 2011 Apr 13. http://www.fda.gov/Drugs/DrugSafety/ucm245164.htm

107. Food and Drug Administration. FDA drug safety communication: safety review update of abacavir and possible increased risk of heart attack. 2011 Mar 1. From FDA website. Accessed 2011 Apr 13. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070263.htm

108. Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010; 201:318-30. http://www.ncbi.nlm.nih.gov/pubmed/20039804?dopt=AbstractPlus

109. Ding X, Andraca-Carrera E, Cooper C et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. Poster presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: 2011 Feb 27– Mar 2 http://www.retroconference.org/2011/Abstracts/42436.htm

110. Gallant JE, Rodriguez AE, Weinberg WG et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005; 192:1921-30. http://www.ncbi.nlm.nih.gov/pubmed/16267763?dopt=AbstractPlus

111. Eron J, Yeni P, Gathe J et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006; 368:476-82. http://www.ncbi.nlm.nih.gov/pubmed/16890834?dopt=AbstractPlus

112. Pulido F, Estrada V, Baril JG et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials. 2009 Mar-Apr; 10:76-87.

115. Post FA, Moyle GJ, Stellbrink HJ et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010; 55:49-57. http://www.ncbi.nlm.nih.gov/pubmed/20431394?dopt=AbstractPlus

116. Smith KY, Patel P, Fine D et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009; 23:1547-56. http://www.ncbi.nlm.nih.gov/pubmed/19542866?dopt=AbstractPlus

120. Hammer SM, Ribaudo H, Bassett R et al. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials. 2010 Nov-Dec; 11:312-24.

121. Moyle G, Higgs C, Teague A et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther. 2006; 11:73-8. http://www.ncbi.nlm.nih.gov/pubmed/16518962?dopt=AbstractPlus

122. Puls RL, Srasuebkul P, Petoumenos K et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010; 51:855-64. http://www.ncbi.nlm.nih.gov/pubmed/20735258?dopt=AbstractPlus

123. Daar ES, Tierney C, Fischl MA et al. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1: A Randomized Trial. Ann Intern Med. 2011; 154:445-456. http://www.ncbi.nlm.nih.gov/pubmed/21320923?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3430716&blobtype=pdf

124. Sax PE, Tierney C, Collier AC et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009; 361:2230-40. http://www.ncbi.nlm.nih.gov/pubmed/19952143?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2800041&blobtype=pdf

125. Martínez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003; 349:1036-46. http://www.ncbi.nlm.nih.gov/pubmed/12968087?dopt=AbstractPlus

126. Green H, Gibb DM, Walker AS et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007; 21:947-55. http://www.ncbi.nlm.nih.gov/pubmed/17457088?dopt=AbstractPlus

127. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002; 359:733-40. http://www.ncbi.nlm.nih.gov/pubmed/11888583?dopt=AbstractPlus

128. Martinez E. The NEFA study: results at three years. AIDS Rev. 2007 Jan-Mar; 9:62.

129. Marcus KA. Supplemental approval release REMS requirement. Silver Spring, MD: US Food and Drug Administration; 2011 May 13. From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/020977s022,020978s026,021205s028,021652s013ltr.pdf

130. Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369:1807-18. http://www.ncbi.nlm.nih.gov/pubmed/24195548?dopt=AbstractPlus

131. Walmsley S, Baumgarten A, Berenguer J et al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015; 70:515-9. http://www.ncbi.nlm.nih.gov/pubmed/26262777?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4645960&blobtype=pdf

132. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382:700-8. http://www.ncbi.nlm.nih.gov/pubmed/23830355?dopt=AbstractPlus

133. US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 205551Orig1s000: Medical review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205551Orig1s000MedR.pdf

134. Musiime V, Kasirye P, Naidoo-James B et al. Once vs twice-daily abacavir and lamivudine in African children. AIDS. 2016; 30:1761-70. http://www.ncbi.nlm.nih.gov/pubmed/27064996?dopt=AbstractPlus

177. Merck & Co., Inc. Zepatier (elbasvir and grazoprevir) tablets prescribing information. Whitehouse Station, NJ; 2016 Jan.

181. Gilead Sciences. Harvoni (ledipasvir and sofosbuvir) tablets prescribing information. Foster City, CA; 2016 Jun.

187. Janssen Products LP. Olysio (simeprevir) capsules prescribing information. Titusville, NJ; 2013 Nov.

198. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV – United States, 2016. From HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

199. Kuhar DT, Henderson DK, Struble KA et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013; 34:875-92. http://www.ncbi.nlm.nih.gov/pubmed/23917901?dopt=AbstractPlus

200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (July 14, 2016). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

201. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in pediatric HIV infection (March 1, 2016). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

202. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, US Department of Health and Human Services (HHS). Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States (October 26, 2016). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

203. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules and oral powder prescribing information. Princeton, NJ; 2014 Jun.

204. Janssen. Prezista (darunavir) oral suspension and tablets prescribing information. Titusville, NJ; 2014 Apr.

205. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2013 Apr.

207. AbbVie Inc. Kaletra (lopinavir/ritonavir) film-coated tablets and oral solution prescribing information. North Chicago, IL; 2013 Nov.

208. ViiV Healthcare. Viracept (nelfinavir mesylate) tablets and oral powder prescribing information. Research Triangle Park, NC; 2012 Apr.

211. Boehringer Ingelheim. Aptivus (tipranavir) capsules and oral solution prescribing information. Ridgefield, CT; 2014 Apr.

213. Bristol-Myers Squibb. Sustiva (efavirenz) capsules and tablets prescribing information. Princeton, NJ; 2014 May.

214. Janssen. Intelence (etravirine) tablets prescribing information. Titusville, NJ; 2013 Feb.

220. Bristol-Myers Squibb. Zerit (stavudine) capsules and oral solution prescribing information. Princeton, NJ; 2012 Jan.

221. Gilead Sciences. Viread (tenofovir disoproxil fumarate) tablets and powder for oral use prescribing information. Foster City, CA; 2013 Oct.

224. ViiV Healthcare. Selzentry (maraviroc) tablets prescribing information. Research Triangle Park, NC; 2011 Nov.

225. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets and chewable tablets prescribing information. Whitehouse Station, NJ; 2014 Apr.

226. Janssen Therapeutics. Edurant (rilpivirine) tablets prescribing information. Titusville, NJ; 2014 May.

228. ViiV Healthcare. Epzicom (abacavir sulfate and lamivudine) tablets prescribing information. Research Triangle Park, NC; 2015 Sep.

229. ViiV Healthcare. Trizivir (abacavir sulfate, lamivudine, and zidovudine) tablets prescribing information. Research Triangle Park, NC; 2015 Sep.

236. ViiV Healthcare. Tivicay (dolutegravir) tablets prescribing information. Research Triangle Park, NC; 2016 Jun.

240. ViiV Healthcare. Triumeq (abacavir, dolutegravir, lamivudine) tablets prescribing information. Research Triangle Park, NC; 2016 Apr.

242. Gilead Sciences Inc. Vitekta (elvitegravir) tablets prescribing information. Foster City, CA; 2015 Jul.

Medical Disclaimer

46. Glaxo Wellcome. Research Triangle Park, NC: Personal communication.

47. Saag MS, Sonnerborg A, Torres RA et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS. 1998; 12:F203-9.

49. Miller V, Sturmer M, Staszewski S et al. The M₁₈₄V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS. 1998; 12:705-12. http://www.ncbi.nlm.nih.gov/pubmed/9619801?dopt=AbstractPlus

50. Staszewski S, Katlama C, Harrer T et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS. 1998; 12:F197-202.

51. Danehower SC, Mitchell CD, Gilbert CA et al. Correlation of phenotypic resistance and clinical efficacy of abacavir in a phase III pediatric study. Int Conf AIDS. 1998; 12:576-7.

53. Reviewers’ comments (personal observations) on Efavirenz 8:18.08.

55. Escaut L, Liotier JY, Albengres E et al. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS. 1999; 13:1419-20. http://www.ncbi.nlm.nih.gov/pubmed/10449301?dopt=AbstractPlus

56. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS. 1999; 13:999-1000. http://www.ncbi.nlm.nih.gov/pubmed/10371187?dopt=AbstractPlus

58. Kent RS, Glaxo Wellcome. Dear health care provider letter regarding fatal hypersensitivity reactions, respiratory symptoms, and Ziagen (abacavir sulfate). Research Triangle Park, NC; 2000 Jan. From FDA web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm169490.htm

59. Gibb DM, Newberry A, Klein N et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet. 2000; 355:1331-2. http://www.ncbi.nlm.nih.gov/pubmed/10776748?dopt=AbstractPlus

60. Harrigan PR, Stone C, Griffin P et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592u89) after monotherapy and combination therapy. J Infect Dis. 2000; 181:912-20. http://www.ncbi.nlm.nih.gov/pubmed/10720512?dopt=AbstractPlus

65. Rubin M. Glaxo Wellcome. Dear health care provider letter regarding severe hypersensitivity reactions following reintroduction with Ziagen (abacavir sulfate) products. Research Triangle Park, NC; 2000 Jul. From FDA web site. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173109.htm

68. Yuen GJ, Lou Y, Thompson NF et al. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol. 2001; 41:277-88. http://www.ncbi.nlm.nih.gov/pubmed/11269568?dopt=AbstractPlus

69. Frissen PH, de Vries J, Weigel HM et al. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS. 2001; 15:289-92. http://www.ncbi.nlm.nih.gov/pubmed/11216946?dopt=AbstractPlus

71. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002; 359:1121-2. http://www.ncbi.nlm.nih.gov/pubmed/11943262?dopt=AbstractPlus

72. Manion DJ. Dear healthcare provider letter: early virologic non-response in patients with HIV infection treated with lamivudine, abacavir, and tenofovir. GlaxoSmithKline; 2003 Jul. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm169490.htm

78. DeJesus E, Herrera G, Teofilo E for the CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004; 39:1038-46. http://www.ncbi.nlm.nih.gov/pubmed/15472858?dopt=AbstractPlus

79. Moyle GJ, DeJesus E, Cahn P for the Ziagen once-daily in Antiretroviral Combination Therapy (CNA30021) Study Team. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen once daily in antiretroviral combination study. J Acquir Immune Defic Syndr. 2005; 38:417-25. http://www.ncbi.nlm.nih.gov/pubmed/15764958?dopt=AbstractPlus

80. Goedken AM, Herman RA. Once-daily abacavir in place of twice-daily administration. Ann Pharmacother. 2005; 39:1302-8. http://www.ncbi.nlm.nih.gov/pubmed/15956231?dopt=AbstractPlus

81. James A. Johann-Liang R. Increased rate and severity of abacavir (ABC) associated hypersensitivity reaction (HSR) in prospective clinical trials. Presented at 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA: 2005 Feb 23. Poster No. 836.

82. Chappuy H, Treluyer JM, Jullien V et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004; 48:4332-6. http://www.ncbi.nlm.nih.gov/pubmed/15504861?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=525408&blobtype=pdf

83. Best BM, Mirochnick M, Capparelli EV et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006; 20:553-60. http://www.ncbi.nlm.nih.gov/pubmed/16470119?dopt=AbstractPlus

84. Capparelli EV, Letendre SL, Ellis RJ et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother. 2005; 49:2504-6. http://www.ncbi.nlm.nih.gov/pubmed/15917556?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1140502&blobtype=pdf

85. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. PNAS. 2004; 101:4180-5. http://www.ncbi.nlm.nih.gov/pubmed/15024131?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=384715&blobtype=pdf

86. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359:727-32. http://www.ncbi.nlm.nih.gov/pubmed/11888582?dopt=AbstractPlus

87. Hughes AR, Mosteller M, Bansal AT et al. Association of genetic variationsin HLA-B region with hypersensitivity to abacavir in some, but not all, population. Pharmacogenomics. 2004; 5:203-11. http://www.ncbi.nlm.nih.gov/pubmed/15016610?dopt=AbstractPlus

89. Rauch A, Nolan D, Martin A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006; 43:99-102. http://www.ncbi.nlm.nih.gov/pubmed/16758424?dopt=AbstractPlus

90. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis. 2006; 43:103-5.

98. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 Screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358:568-79. http://www.ncbi.nlm.nih.gov/pubmed/18256392?dopt=AbstractPlus

99. Saag M, Balu R, Phillips E et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008; 46:1111-8. http://www.ncbi.nlm.nih.gov/pubmed/18444831?dopt=AbstractPlus

100. Hughes S, Hughes A, Brothers C et al. PREDICT-1 (CNA 106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2008; 7:121-9. http://www.ncbi.nlm.nih.gov/pubmed/17534855?dopt=AbstractPlus

101. Cutrell A, Brothers C, Yeo J et al. Abacavir and the potential risk of myocardial infarction. Lancet. 2008; 371:1413. Letter. http://www.ncbi.nlm.nih.gov/pubmed/18387668?dopt=AbstractPlus

102. D:A:D study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study; a multi-cohort collaboration. Lancet. 2008; 371:1417-26.